Sudden death in hypertrophic cardiomyopathy: Old risk factors re-assessed in a new model of maximalized follow-up

European Heart Journal

Volumn 31, Issue 24, 2010, Pages 3084-3093

  Dimitrow, Paweł Petkow ^a   Chojnowska, Lidia ^b   Rudziński, Tomasz ^c   Piotrowski, Walerian ^b   Ziółkowska, Lidia ^d   Wojtarowicz, Andrzej ^e   Wycisk, Anna ^f   Dbrowska Kugacka, Alicja ^g   Nowalany Kozielska, Ewa ^f   Sobkowicz, Boena ^h   Wróbel, Wojciech ^f   Aleszewicz Baranowska, Janina ^g   Rynkiewicz, Andrzej ^g   Łoboz Grudzień, Krystyna ⁱ   Marchel, Michał ^j   Wysokiński, Andrzej ^k  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF CARDIOLOGY   (Poland)

^c University of Medical Sciences   (Poland)

^d CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^e POMERANIAN MEDICAL UNIVERSITY   (Poland)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

ⁱ WROCLAW MEDICAL UNIVERSITY   (Poland)

^j MEDICAL UNIVERSITY OF WARSAW   (Poland)

^k MEDICAL UNIVERSITY OF LUBLIN   (Poland)

more..

Author keywords

Hypertrophic cardiomyopathy; Risk factors; Sudden death

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CLINICAL ASSESSMENT; FEMALE; FOLLOW UP; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PRIORITY JOURNAL; RISK FACTOR; SUDDEN DEATH; SURVIVAL RATE;

AGE FACTORS; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; EXERCISE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PEDIGREE; POLAND; PROGNOSIS; RISK FACTORS; SYNCOPE;

EID: 78650398672     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq308     Document Type: Article

References (37)

1. Moss AJ, Zareba W, Kaufman ES, Gartman E, Peterson DR, Benhorin J, Towbin JA, Keating MT, Priori SG, Schwartz PJ, Vincent GM, Robinson JL, Andrews ML, Feng C, Hall WJ, Medina A, Zhang L, Wang Z. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002;105: 794-799.
2. Goldenberg I, Moss AJ, Zareba W, McNitt S, Robinson JL, Qi M, Towbin JA, Ackerman MJ, Murphy L. Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome. J Cardiovasc Electrophysiol 2006;17: 1161-1168.
3. Liu JF, Moss AJ, Jons C, Benhorin J, Schwartz PJ, Spazzolini C, Crotti L, Ackerman MJ, McNitt S, Robinson JL, Qi M, Goldenberg I, Zareba W. Mutation-specific risk in two genetic forms of type 3 long QT syndrome. Am J Cardiol 2010; 105:210-213.
4. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000;35:36-44.
5. Elliott P, Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice. Heart 2008;94:1269-1275.
6. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363: 1881-1891.
7. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287: 1308-1320.
8. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858-864.
9. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA 3rd, Spirito P. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-373.
10. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326: 1108-1114.
11. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG, Seidman CE. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardio-myopathy. N Engl J Med 1995;332:1058-1064.
12. Perkins MJ, Van Driest SL, Ellsworth EG, Will ML, Gersh BJ, Ommen SR, Ackerman MJ. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J 2005;26:2457-2462.
13. Lechin M, Quiñones MA, Omran A, Hill R, Yu QT, Rakowski H, Wigle D, Liew CC, Sole M, Roberts R, Marian AJ. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyo-pathy. Circulation 1995;92:1808-1812.
14. Spirito P, Autore C, Rapezzi C, Bernabò P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, Estes NA, Barillà CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ. Syncope and risk of sudden death in hypertrophic cardiomyo-pathy. Circulation 2009;119:1703-1710.
15. Sorajja P, Nishimura RA, Ommen SR, Ackerman MJ, Tajik AJ, Gersh BJ. Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr 2006;19:788-795.
16. Ostman-Smith I, Wettrell G, Keeton B, Holmgren D, Ergander U, Gould S, Bowker C, Verdicchio M. Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur Heart J 2008;29:1160-1167.
17. Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, Lurie PR, Orav EJ, Towbin JA. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007;115:773-781.
18. Lekanne Deprez RH, Muurling-Vlietman JJ, Hruda J, Baars MJ, Wijnaendts LC, Stolte-Dijkstra I, Alders M, van Hagen JM. Two cases of severe neonatal hyper-trophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene. J Med Genet 2006;43:829-832.
19. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42: 873-879.
20. Elliott P, McKenna W. The science of uncertainty and the art of probability: syncope and its consequences in hypertrophic cardiomyopathy. Circulation 2009; 119:1697-1699.
21. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-2218.
22. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED, American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents; European Society of Cardiology Committee for Practice Guidelines. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-1991.
23. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002;87:169-176.
24. Gimeno JR, Tomé-Esteban M, Lofiego C, Hurtado J, Pantazis A, Mist B, Lambiase P, McKenna WJ, Elliott PM. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009;30:2599-2605.
25. Ommen SR, Gersh BJ. Sudden cardiac death risk in hypertrophic cardiomyopathy. Eur Heart J 2009;30:2558-2559.
26. Elliott PM, Gimeno JR, Tomé MT, Shah J, Ward D, Thaman R, Mogensen J, McKenna WJ. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-1941.
27. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopa-thy. N Engl J Med 2000;342:1778-1785.
28. Nugent AW, Daubeney PE, Chondros P, Carlin JB, Colan SD, Cheung M, Davis AM, Chow CW, Weintraub RG, National Australian Childhood Cardio-myopathy Study. Clinical features and outcomes of childhood hypertrophic cardi-omyopathy: results from a national population-based study. Circulation 2005;112: 1332-1338.
29. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:147-153.
30. Maron BJ, Tajik AJ, Ruttenberg HD, Graham TP, Atwood GF, Victorica BE, Lie JT, Roberts WC. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 1982;65:7-17.
31. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532-538.
32. Suda K, Kohl T, Kovalchin JP, Silverman NH. Echocardiographic predictors of poor outcome in infants with hypertrophic cardiomyopathy. Am J Cardiol 1997; 80:595-600.
33. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, Tome Esteban MT, McKenna WJ. Historical trends in reported survival rates in patients with hyper-trophic cardiomyopathy. Heart 2006;92:785-791.
34. Michaud K, Lesta Mdel M, Fellmann F, Mangin P. Molecular autopsy of sudden cardiac death: from postmortem to clinical approach. Rev Med Suisse 2008;4:1590-1593.
35. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.
36. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006;91:1187-1192.
37. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, Shalaby A, Schaechter A, Subacius H, Kadish A, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006;113:776-782.